Hiroyoshi Nishikawa, MD, PhD, discusses Imaging Mass Cytometry in his presentation titled Comprehensive Landscape of the Tumor Microenvironment Analyzed with CyTOF Technology.
Immune escape mechanisms such as the induction or recruitment of immunosuppressive cells and the increased expression of various immunosuppressive molecules including PD-1/PD-1 ligands are essential processes during cancer development and progression, leading to the development of complex immune-suppressive networks in the tumor microenvironment. Thus, high-dimensional immune profiling using CyTOF® technology for single-cell phenotype and function analysis plays an important role in developing more effective cancer immunotherapeutic strategies and in defining biomarkers for stratifying responders and nonresponders via the detailed analysis of immune responses in cancer patients.
About this webinar:
In this presentation from the July 2020 Fluidigm Oncology and Infectious Disease Virtual Summit, Nishikawa outlines the current status of cancer immunotherapy and recent advances in the field. He also describes:
- The importance of biomarkers in the cancer immunotherapy field and in PD-1 blockade therapy
- His work in assessing a strong suppressive tumor microenvironment in EGFR-mutated non-small cell lung carcinoma (NSCLC) tumors
- How Imaging Mass Cytometry™ is used to understand the localization of tumor antigen-specific T cells
About the presenter:
Hiroyoshi Nishikawa, MD, PhD
Division Chief of Cancer Immunology
Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC)
National Cancer Center, Tokyo/Chiba, Japan
Professor of Immunology
Nagoya University Graduate School of Medicine
Professor Hiroyoshi Nishikawa is Division Chief of Cancer Immunology at the Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC) at the National Cancer Center Japan and a Professor of Immunology at Nagoya University Graduate School of Medicine. Throughout his career his research has focused on tumor biology, tumor therapeutics and immunology. Currently his group aims to comprehensively investigate immune cells such as CD4+, CD8+ T cells and macrophages, cancer cells and environmental factors to clarify the molecular mechanisms that control immune balances in a tumor microenvironment.
For Research Use Only. Not for use in diagnostic procedures.